September 06, 2008
Home
About
Submit Press Release
PR Firms
Editors/Journalists
Search Archives
 
News Releases by Category  
News by Country  
News by MSA  
All News for Today  
Browse News by Day  
News by Trackbacks  
All Press Releases for May 6, 2008 Subscribe to this News Feed  
 

New Promotion Launched: Get 1 Free Pack of Feline Leukemia and Feline Immunodeficiency Virus Treatment Aid from IMULAN

Download this press release as an Adobe PDF document.

Save on Lymphocyte T-Cell Immunomodulator (LTCI) from IMULAN BioTherapeutics, the first and only conditionally approved treatment aid in the United States for Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV or Feline AIDS) infections.

Prescott, AZ (PRWEB) May 5, 2008 -- IMULAN BioTherapeutics (IMULAN) announced a "Buy 1 Pack, Get 1 Pack Free" promotion on Lymphocyte T-Cell Immunomodulator (LTCI), the first and only approved treatment aid in the United States for Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV or Feline AIDS) infections. For every order a veterinarian places for LTCI before June 15, 2008, IMULAN will match that order with free product.

FeLV and FIV Can Be Treated With LTCI
FeLV and FIV Can Be Treated With LTCI

Buy 1 Pack, Get 1 Pack Free
Dr. Craig Woods, CEO of IMULAN, stated, "In appreciation for making our launch of LTCI a tremendous success, IMULAN is pleased to offer this promotion to help cats infected with FeLV and FIV."

Lymphocyte T-Cell Immunomodulator is a naturally occurring substance produced by the body. In previous studies, Lymphocyte T-Cell Immunomodulator has demonstrated improvement in the clinical symptoms and lymphocyte counts in cats infected with FeLV and FIV.

LTCI and the "Buy 1 Pack, Get 1 Pack Free" promotion are only available through licensed veterinarians in the United States. Cat owners are encouraged to contact their veterinarian for additional information about LTCI, feline leukemia virus (FeLV), or feline immunodeficiency virus (FIV or Feline AIDS) infections.

For additional information on LTCI or IMULAN, please call 877-892-9595 or visit www.IMULAN.com.

About Lymphocyte T-Cell Immunomodulator:
LTCI is a conditionally approved treatment aid for cats infected with Feline Leukemia Virus (FeLV) and/or Feline Immunodeficiency Virus (FIV). Conditional licenses are granted by the United States Department of Agriculture Center for Veterinary Biologics to products that have met reasonable expectation of efficacy, have demonstrated purity, and passed safety testing. Additional efficacy and potency testing is in progress. LTCI is manufactured by T-Cyte Therapeutics, Inc. and is exclusively distributed by IMULAN BioTherapeutics, LLC.

About IMULAN BioTherapeutics:
IMULAN is a privately held bioscience company focused on providing innovative solutions for complex animal diseases. IMULAN's policy is to provide veterinarians access to conditionally approved products for diseases where no current approved therapy is available. IMULAN's products give animal owners better solutions for their pet's diseases.

Contact:
Dr. Craig Woods, CEO
IMULAN BioTherapeutics
877-892-9595
cwoods @ imulan.com

###

Trackback URL: http://www.prweb.com/pingpr.php/SW5zZS1QaWdnLUNyYXMtRmFsdS1GYWx1LVplcm8=


See the original story at: http://www.prweb.com/releases/feline-leukemia/felv-fiv/prweb908854.htm
Email this story to a colleague
Printer Friendly Version
Bookmark with del.icio.us
Bookmark with Y!MyWeb
Submit to Digg
Dr. Craig Woods
IMULAN BioTherapeutics
877-892-9595
Email us Here

Press Release Attachment
IMULAN BioTherapeutics
Uploaded: Mar 4, 2008
File Name: imulanlogo.jpg

Press Release Attachment
Precision Immune Therapies For Veterinary Medicine
Uploaded: Mar 4, 2008
File Name: imulantagline.jpg

If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2007, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright